Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/6/2024 | $57.00 → $79.00 | Equal Weight → Overweight | Barclays |
3/6/2024 | $48.00 | Equal Weight | Barclays |
8/31/2023 | $40.00 | Buy | Truist |
3/31/2023 | $30.00 | Market Outperform | CJS Securities |
3/3/2023 | $30.00 | Mkt Perform → Outperform | Raymond James |
8/12/2021 | Outperform → Market Perform | Raymond James | |
8/12/2021 | $39.00 | Overweight | Barclays |
Barclays upgraded RadNet from Equal Weight to Overweight and set a new price target of $79.00 from $57.00 previously
Barclays initiated coverage of RadNet with a rating of Equal Weight and set a new price target of $48.00
Truist initiated coverage of RadNet with a rating of Buy and set a new price target of $40.00
Total Company Revenue increased 14.7% to $461.1 million in the third quarter of 2024 from $402.0 million in the third quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 34.3% to $16.4 million in the third quarter of 2024 from $12.2 million in the third quarter of 2023Digital Health Revenue growth resulted in part from a $2.2 million (or 75.8%) increase in AI Revenue, which climbed to $5.1 million during the third quarter of 2024 from $2.9 million in the third quarter of 2023Total Company Adjusted EBITDA(1) was $73.7 million in the third quarter of 2024 as compared with $57.9 million in the third quarter of 2023, an increase of 27
LOS ANGELES, Oct. 25, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers, announced today that it will host a conference call to discuss its third quarter 2024 financial results on Monday, November 11, 2024 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time). Investors are invited to listen to RadNet's conference call by dialing 844-826-3035. International callers can dial 412-317-5195. There will also be simultaneous and archived webcasts available at https://viavid.webcasts.com/starthere.jsp?ei=1691984&tp_key=8cbf05cc88. An arch
Total Company Revenue increased 13.9% to $459.7 million in the second quarter of 2024 from $403.7 million in the second quarter of 2023; Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 36.4% to $15.8 million in the second quarter of 2024 from $11.6 million in the second quarter of 2023Digital Health Revenue growth resulted in part from a $3.2 million (or 136.6%) increase in AI Revenue, which climbed to $5.6 million during the second quarter of 2024 from $2.4 million in the second quarter of 2023Total Company Adjusted EBITDA(1) was $72.3 million in the second quarter of 2024 as compared with $60.4 million in the second quarter of 2023, an incre
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
SC 13G/A - RadNet, Inc. (0000790526) (Subject)
LOS ANGELES, Jan. 08, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Dr. Howard Berger, President and Chief Executive Officer, Mark Stolper, Executive Vice President and Chief Financial Officer and Dr. Gregory Sorensen, Executive Vice President and Chief Science Officer will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Wednesday, January 15, 2025 at 3:00 p.m. PST. A live webcast of RadNet's presentation can be accessed through the following link, https://jpm
CAMBRIDGE, Mass., Dec. 4, 2024 /PRNewswire/ -- Ketryx announced today that DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. (NASDAQ:RDNT), has selected Ketryx to accelerate the delivery of AI-powered health informatics solutions. DeepHealth's solutions leverage a cloud-native operating system to drive operational efficiency, improved clinical confidence, and better care delivery. According to the FDA, radiology leads the way in AI/ML adoption within the SaMD sector, with 79% of newly approved devices in the field using these technologies to enhance diagnostics and patient care.
LOS ANGELES, Dec. 02, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers, today announced that Mark Stolper, Executive Vice President and Chief Financial Officer, will be presenting at the BofA Securities 2024 Leveraged Finance Conference in Boca Raton, FL on Tuesday, December 3, 2024 at 8:10 a.m. Eastern Time (5:10 a.m. Pacific Time). There will be simultaneous and archived webcasts available at https://bofa.veracast.com/webcasts/bofa/levfin2024/idALc0oT.cfmand www.radnet.com under the "About RadNet'' menu section and "News a
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
4 - RadNet, Inc. (0000790526) (Issuer)
SCHEDULE 13G/A - RadNet, Inc. (0000790526) (Subject)
8-K - RadNet, Inc. (0000790526) (Filer)
10-Q - RadNet, Inc. (0000790526) (Filer)
Former Chief Business Leader of Philips' multi-billion-dollar Precision Diagnosis division and member of Philips' Executive CommitteeEnd-to-end responsibility for Philip's CT, MR, dXR, Ultrasound and Diagnostic Informatics (radiology software) businessesProven track record of building and managing radiology software solutions, including significant experience with AI development and commercialization LOS ANGELES, Sept. 12, 2024 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ:RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of fully-owned and operated outpatient imaging centers and digital health solutions, announced today the appo